Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075066 | 1.00 | SLC6A4 (0.67) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2069976 | 1.00 | SLC6A4 (0.67) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL12933607 | 0.88 | SLC6A4 (0.53) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2075294 | 0.87 | SLC6A4 (0.52) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2074223 | 0.87 | SLC6A4 (0.52) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2074694 | 0.87 | SLC6A4 (0.51) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2071694 | 0.86 | SLC6A2 (0.51) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2075118 | 0.86 | SLC6A4 (0.51) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A | |
| SCHEMBL2074733 | 0.86 | SLC6A4 (0.50) | SLC6A4SLC6A2CYP2D6KCNH2GPR84 | |
| SCHEMBL2075086 | 0.85 | SLC6A4 (0.69) | SLC6A4SLC6A2CYP2D6KCNH2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1756054-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2005118539-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | SLC6A4 14/4885SLC6A2 9/4885CYP2D6 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.